CANCER BREAST COMPREHENSIVE PANEL

ER & PR receptor assays are routinely performed on Breast carcinomas to assess reponsiveness to endocrine therapy and prognosis. Her-2 expression shows responsiveness to Herceptin therapy. Addition of Ki-67 further helps as a predictive and prognostic markerThese biomarkers are used for better understanding of the kinetics and effectiveness of a drug. It detects early signals of efficacy for rapidly evaluating the impact of potential disease-modifying therapies.

  • Test Type:
  • Pre-test Information:
    Provide brief clinical history.
  • Report Delivery:
    Sample by Tues 9 am; Report 10 days
  • Components:
    0